Wed, 14 Oct | Webinar

Japanese Early-Stage Technology Companies - Opportunities for Collaboration and Investment

Global Business Pitch Session Join a pitching session with early-stage Japanese life sciences SMEs presenting their latest innovations. Discover opportunities for overseas partnerships and investment with some of the most vibrant scientific communities in the world.
Registration is Closed
Japanese Early-Stage Technology Companies - Opportunities for Collaboration and Investment

Time & Location

14 Oct 2020, 10:00 BST
Webinar

About the Event

Japan Healthcare Venture Summit 

Japanese Early-Stage Technology Companies

Opportunities for Collaboration and Investment 

~Global Business Pitch Session~

14 October 2020 (10 am BST, 11 am CET, 6 pm JST) Webinar 

Join a pitching session with early-stage Japanese life sciences SMEs presenting their latest innovations. Discover opportunities for overseas partnerships and investment with some of the most vibrant scientific communities in the world.

Oxentia and the Mitsubishi Research Institute work in partnerships to support Japanese life science SMEs through funding, coaching and business mentoring. Their mission is to ensure the successful commercialisation of products and services for the good of societies around the world.

Presentations

5 minutes presentation and 3 minutes Q&A sessions

  • Sleep Apnea Syndrome (SAS) Screening and its new application for preventing  Covid-19

 Quantum Operation

  • Highly purified Mesenchymal Stem Cell “REC” targeting bone formation disorders including ultra-orphan Hypophosphatasia

 PuREC

  • VR headset with eye-tracking system

 FOVE

  • Development of a novel nucleic acid therapeutic drug for severe asthma

 TAK-Circulator

  • Mathematics and Technology for visualizing and perceiving hidden things around the world ~Human body, Energy, Building, Planets~

  Integral Geometry Science

  • Revolutionizing the Way We Treat Heart Failure ~ Development of novel cell-based therapeutics and a delivery method towards a FIH trial

 Metcela

  • Human neural stem cell "OligoGenie" as a new therapeutic agent for central nervous system disorders

 Oligogen

  • Cancer gene therapy using a REIC/Dkk‑3 gene with PD-1 inhibitor

 Momotaro-Gene

Share This Event